Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,044.35 +8.66 (+0.17%) Dow
38,048.77 +232.85 (+0.62%) Nasdaq
15,714.25 +56.43 (+0.36%) Bitcoin USD
57,243.00 -2,906.85 (-4.83%) CMC Crypto 200
1,214.46 -124.61 (-9.31%)
Innoviva, Inc. (INVA)
| Previous close | 15.11 |
| Open | 15.18 |
| Bid | 15.19 x 400 |
| Ask | 15.24 x 200 |
| Day's range | 15.01 - 15.34 |
| 52-week range | 11.40 - 16.86 |
| Volume | |
| Avg. volume | 717,100 |
| Market cap | 950.906M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 6.91 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 08 Sept 2015 |
| 1y target est | N/A |
- Business Wire
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
WALTHAM, Mass., April 24, 2024--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation given by the Global Antibiotic Research & Development Partnership (GARDP) at the European Society of Clinical Microbiology and Infectious Disease Global Congress (ESCMID Global 2024) taking place April 27-30, 2024, in Barcelona, Spain. Zoliflodacin is a first
- PR Newswire
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the C
- Business Wire
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif., February 29, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted select corporate achievements.
